Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12617858 | Anti-Müllerian hormone receptor 2 antibodies and methods of use | 🖼🧊📄§ | 2026-05-05 | 2041-01-29 | 0 | 31 |
| 12616665 | Neutrophil-to-lymphocyte ratio decreasing agent | 🖼🧊📄§ | 2026-05-05 | 2041-11-12 | 0 | 31 |
| 12617861 | Anti-OX40 antibody and method of treatment | 🖼🧊📄§ | 2026-05-05 | 2041-04-16 | 0 | 31 |
| 12616662 | Lipid particles for nucleic acid delivery and clinical applications of same | 🖼🧊📄§ | 2026-05-05 | 2042-11-17 | 0 | 31 |
| 12617791 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | 🖼🧊📄§ | 2026-05-05 | 2041-10-15 | 0 | 31 |
| 12617809 | Cardioprotective lipid and method of use | 🖼🧊📄§ | 2026-05-05 | 2042-09-22 | 0 | 31 |
| 12617014 | AU, AG and rich phytochemical payload nanomaterials, antiviral/antibacterial products and synthesis methods | 🖼🧊📄§ | 2026-05-05 | 2042-05-10 | 0 | 31 |
| 12616656 | Adventitial painting modality of local drug delivery to abate intimal hyperplasia | 🖼🧊📄§ | 2026-05-05 | 2042-05-20 | 0 | 31 |
| 12616734 | Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-27 | 0 | 31 |
| 12618046 | Generation of tumor immunity using astrocytes and astrocyte-dendritic cell combinations | 🖼🧊📄§ | 2026-05-05 | 2043-03-28 | 0 | 31 |
| 12618045 | Automated method for preparing retinal pigment epithelium cells | 🖼🧊📄§ | 2026-05-05 | 2040-06-19 | 0 | 31 |
| 12618063 | Pan-genotypic agents against influenza virus and methods of using the same | 🖼🧊📄§ | 2026-05-05 | 2044-07-16 | 0 | 31 |
| 12618076 | Methods of engineering platelets for targeting circulating tumor cells | 🖼🧊📄§ | 2026-05-05 | 2040-09-30 | 0 | 31 |
| 12618082 | Engineered muscle targeting compositions | 🖼🧊📄§ | 2026-05-05 | 2042-03-29 | 0 | 31 |
| 12617792 | Purine derivative, intermediate and application thereof in preparing anticancer medicine | 🖼🧊📄§ | 2026-05-05 | 2040-10-21 | 0 | 31 |
| 12617757 | Compounds and modules for inhibition of pre-miR-21 and their use in treatment of certain cancers | 🖼🧊📄§ | 2026-05-05 | 2040-10-29 | 0 | 31 |
| 12617759 | Modifier of four-membered ring derivative, preparation method and application thereof | 🖼🧊📄§ | 2026-05-05 | 2040-10-29 | 0 | 31 |
| 12617762 | Carboxy derivatives with antiinflamatory properties | 🖼🧊📄§ | 2026-05-05 | 2040-12-23 | 0 | 31 |
| 12617790 | Mitragynine analogs and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12617805 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-19 | 0 | 31 |
| 12617811 | HPK1 inhibitors and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-07-02 | 0 | 31 |
| 12617812 | Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-25 | 0 | 31 |
| 12617807 | Long lasting opioid reversal using hydrogen peroxide-induced release in blood | 🖼🧊📄§ | 2026-05-05 | 2042-04-01 | 0 | 31 |
| 12617820 | Engineered coronavirus spike (s) protein and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12617828 | Genetically modified immune cell, preparation method therefor, and application | 🖼🧊📄§ | 2026-05-05 | 2040-05-06 | 0 | 31 |
| 12617826 | CLEC2 fusion protein and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-09-29 | 0 | 31 |
| 12617831 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | 🖼🧊📄§ | 2026-05-05 | 2040-02-21 | 0 | 31 |
| 12617836 | Tumor environment specific expression of effector genes | 🖼🧊📄§ | 2026-05-05 | 2042-03-21 | 0 | 31 |
| 12617841 | Nucleic acid antibody constructs for use against respiratory syncytial virus | 🖼🧊📄§ | 2026-05-05 | 2039-01-31 | 0 | 31 |
| 12617843 | Human broadly neutralizing antibodies against the membrane-proximal external region of HIV Env for vaccine design and intervention | 🖼🧊📄§ | 2026-05-05 | 2040-10-14 | 0 | 31 |
| 12617850 | Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody | 🖼🧊📄§ | 2026-05-05 | 2042-03-22 | 0 | 31 |
| 12617849 | Antigen specific CD19-targeted CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2040-04-29 | 0 | 31 |
| 12617851 | TREM2 antibodies and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-05 | 0 | 31 |
| 12617856 | Protease-cleavable substrates and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-03-17 | 0 | 31 |
| 12617870 | Methods of reversing ticagrelor activity | 🖼🧊📄§ | 2026-05-05 | 2039-09-20 | 0 | 31 |
| 12617864 | Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-04-12 | 0 | 31 |
| 12617866 | Humanized antibodies to mucin-16 and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-07 | 0 | 31 |
| 12618838 | Single domain VHH antibodies against SARS-CoV-2 virus | 🖼🧊📄§ | 2026-05-05 | 2042-11-15 | 0 | 31 |
| 12618031 | Delivery devices | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12618048 | Dual CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2041-07-30 | 0 | 31 |
| 12616681 | Compositions and methods for treating renal injury | 🖼🧊📄§ | 2026-05-05 | 2042-08-22 | 0 | 31 |
| 12616677 | Injectable pharmaceutical compositions and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-01 | 0 | 31 |
| 12616678 | Methods to of aldehyde dehydrogenases for treatment of cancer | 🖼🧊📄§ | 2026-05-05 | 2041-06-10 | 0 | 31 |
| 12616689 | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects | 🖼🧊📄§ | 2026-05-05 | 2043-08-30 | 0 | 31 |
| 12616690 | Specific AKT3 activator and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2044-03-15 | 0 | 31 |
| 12616687 | Treatment of viral infection, disease or disorder using a selective sir agonist | 🖼🧊📄§ | 2026-05-05 | 2042-11-04 | 0 | 31 |
| 12616700 | Therapeutic regimen | 🖼🧊📄§ | 2026-05-05 | 2043-07-07 | 0 | 31 |
| 12616698 | Methods for reducing liver fat and for treating fatty liver disorders | 🖼🧊📄§ | 2026-05-05 | 2043-11-22 | 0 | 31 |
| 12616697 | Methods of treatment with myosin modulator | 🖼🧊📄§ | 2026-05-05 | 2041-08-26 | 0 | 31 |
| 12616709 | Pharmaceutical composition for treating sepsis and use thereof | 🖼🧊📄§ | 2026-05-05 | 2041-03-23 | 0 | 31 |